For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of
vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed
and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical
concern. This may be due to various reasons, including new dosing recommendations as well as
an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity.
This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin